Cordis To Enroll 400 Patients In SIRIUS Trial After Conditional IDE
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis unit announced plans to begin enrolling 400 of the 1,100 patients selected for its Rapamune-eluting coronary stent clinical trial in the U.S. immediately following conditional investigational device exemption approval by FDA on Feb. 5.
You may also be interested in...
Cook, Inc. Coated Stent IDE Clearance Follows J&J/Cordis By One Month
Cook, Inc.' s March 2 investigational device exemption clearance appears to have cut Johnson & Johnson's six to eight-month lead in bringing a drug-eluting stent to the U.S. market by at least half.
Cook, Inc. Coated Stent IDE Clearance Follows J&J/Cordis By One Month
Cook, Inc.' s March 2 investigational device exemption clearance appears to have cut Johnson & Johnson's six to eight-month lead in bringing a drug-eluting stent to the U.S. market by at least half.
Boston Scientific Hedges Bets In Drug-Coated Stents With Quanam Buy
Boston Scientific's expansion of its drug-coated coronary stent R&D program through acquisition of Quanam could accelerate its European market entry by up to six months, the firm says.